Journal
MEDICINAL CHEMISTRY RESEARCH
Volume 29, Issue 6, Pages 962-978Publisher
SPRINGER BIRKHAUSER
DOI: 10.1007/s00044-020-02537-0
Keywords
Allosteric; BRCA; Histone 4; PARP1; Synthetic lethality
Categories
Funding
- National Institutes of Health/National Cancer Institute [R01 CA186238]
- Polish National Science Centre
Ask authors/readers for more resources
The successful use of PARP1 inhibitors like olaparib (Loparza (R)) in the treatment of BRCA1/2-deficient breast cancer has provided clinical proof-of-concept for applying personalized medicine based on synthetic lethality to the treatment of cancer. Unfortunately, all marketed PARP1 inhibitors act by competing with the cofactor NAD(+) and resistance is already developing to this anticancer mechanism. Allosteric PARP1 inhibitors could provide a means of overcoming this resistance. A high throughput screen performed by Tulin et al. identified 5F02 as an allosteric PARP inhibitor that acts by preventing the enzymatic activation of PARP1 by histone H4. 5F02 demonstrated anticancer activity in several cancer cell lines and was more potent than olaparib and synergistic with olaparib in these assays. In the present study, we explored the structure-activity relationship of 5F02 by preparing analogs that possessed structural variation in four regions of the chemical scaffold. Our efforts led to lead molecule 7, which demonstrated potent anti-clonogenic activity against BRCA-deficient NALM6 leukemia cells in culture and a therapeutic index for the BRCA-deficient cells over their BRCA-proficient isogenic counterparts.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available